O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+32.08%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$4.99B
AUM Growth
+$4.99B
(+7.1%)
Cap. Flow
-$375M
Cap. Flow
% of AUM
-7.51%
Top 10 Holdings %
Top 10 Hldgs %
36.59%
Holding
136
New
14
Increased
17
Reduced
27
Closed
25
Top Buys
| 1 |
Eli Lilly
LLY
|
$105M |
| 2 |
Biogen
BIIB
|
$70.1M |
| 3 |
Elevance Health
ELV
|
$66.7M |
| 4 |
Scholar Rock
SRRK
|
$41.6M |
| 5 |
argenx
ARGX
|
$19.8M |
Top Sells
| 1 |
Humana
HUM
|
$106M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$85.3M |
| 3 |
Baxter International
BAX
|
$84.5M |
| 4 |
Cigna
CI
|
$66.2M |
| 5 |
AbbVie
ABBV
|
$49.2M |
Sector Composition
| 1 | Healthcare | 98.25% |
| 2 | Industrials | 1.02% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
GoodRx Holdings
GDRX
$1.49B
| – | – |
-1,595,000
| Closed | -$8.98M |
|
127
Altimmune
ALT
$325M
| – | – |
-100,000
| Closed | -$260K |
|
128
Akero Therapeutics
AKRO
$3.65B
| – | – |
-350,000
| Closed | -$17.7M |
|
|
129
AbbVie
ABBV
$374B
| – | – |
-330,000
| Closed | -$49.2M |
|
130
ESSA Pharma
EPIX
$11.2M
| – | – |
-842,366
| Closed | -$2.6M |
|
|
131
Cigna
CI
$80.2B
| – | – |
-231,500
| Closed | -$66.2M |
|
132
BioAtla
BCAB
$28.7M
| – | – |
-1,009,279
| Closed | -$1.72M |
|
|
133
Baxter International
BAX
$12.1B
| – | – |
-2,239,900
| Closed | -$84.5M |
|
134
AstraZeneca
AZN
$255B
| – | – |
0
| – | – |
|
135
Arcutis Biotherapeutics
ARQT
$1.91B
| – | – |
-1,914,479
| Closed | -$10.2M |
|